Race Oncology
Race Oncology Logo
About Race Oncology
Race Oncology Ltd is a clinical stage biopharmaceutical company focused on developing innovative cancer therapies. Its lead product, bisantrene (RC220), is a small molecule chemotherapeutic with demonstrated benefits in adult and paediatric patients. The company is advancing RC220 to address unmet needs in oncology, particularly in anthracycline combinations for cardioprotection and enhanced anticancer activity in solid tumors. Race Oncology is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia and investigating its effect on the m6A RNA pathway. The company collaborates with leading research institutions and serves patients worldwide.
Address
Gateway, 1 Macquarie Place, Level 36
Sydney, 2000
Australia
Year founded
2011
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
